APA (7th ed.) Citation

Chiu, H., Kuo, C., Lai, M., Wu, R., Chen, C., Chiu, C., . . . Le, P. (2024). Superior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: A real-world cohort study. BMC Gastroenterology, 24(1), 1. https://doi.org/10.1186/s12876-024-03577-1

Chicago Style (17th ed.) Citation

Chiu, Horng-Yih, Chia-Jung Kuo, Ming-Wei Lai, Ren-Chin Wu, Chien-Ming Chen, Cheng-Tang Chiu, Yu-Bin Pan, Cheng-Hsun Chiu, and Puo-Hsien Le. "Superior Persistence of Ustekinumab Compared to Anti-TNF in Vedolizumab-experienced Inflammatory Bowel Diseases Patients: A Real-world Cohort Study." BMC Gastroenterology 24, no. 1 (2024): 1. https://doi.org/10.1186/s12876-024-03577-1.

MLA (9th ed.) Citation

Chiu, Horng-Yih, et al. "Superior Persistence of Ustekinumab Compared to Anti-TNF in Vedolizumab-experienced Inflammatory Bowel Diseases Patients: A Real-world Cohort Study." BMC Gastroenterology, vol. 24, no. 1, 2024, p. 1, https://doi.org/10.1186/s12876-024-03577-1.